Orphan Medical: The Sales Representative and the Medical Information Form

Orphan Medical’s Xyrem off-label promotion case shows a division inside the company’s sales operation: a sales consultant had to use a medical information request form when asked about an off-label use, while a physician employed as a promotional speaker could answer. The same product, the same question, a different person allowed to answer.

Xyrem and the Medical Information Request Form

The medical information request form was Orphan Medical’s prescribed response when a Xyrem sales consultant received an off-label question. The consultant was not permitted to answer it. The court’s account of the company’s procedures distinguished that restriction from the permission given to physicians employed as promotional speakers for the same drug.

For an employee who knows that process, the useful questions concern the handoff: what the prescriber asked, what the representative said, and how the physician speaker became involved. We examine that connection with insiders who know the difference between the procedure on paper and the conversation in the room.

What Is Considered Off-Label Promotion?

Off-label promotion is a manufacturer’s promotion of a drug for a use outside the labeling approved by the Food and Drug Administration. The Xyrem dispute concerned the manufacturer’s promotional communications through its sales representative.

What a company promotes, what a physician prescribes and what a government program pays for belong to different parts of the transaction. An insider may see the sales instruction without seeing the claim, or the reimbursement work without hearing the original pitch.

The connection between off-label promotion and false claims concerns how the manufacturer’s conduct reaches a request for government money.

When the Sales Message Outruns the Study

A sales training document can show how a company turned a study’s limitations into a promotional answer. In a separate case involving ISTA Pharmaceuticals, a whistleblower alleged that representatives received instructions for answering challenges to a study whose results were not statistically significant. According to the complaint, the company trained them to describe an off-label use of Xibrom as trending toward superiority.

That allegation concerns how the company equipped its sales force to handle an inconvenient result. The study and the company’s prescribed sales response can be read beside each other. For an employee who helped design the pitch, the valuable knowledge is why the company chose those words and which uses it expected them to sell. The question of truthful, nonmisleading promotion starts with what the science actually says.

The same complaint alleged that ISTA encouraged representatives to spend part of their budgets printing preoperative instruction sheets for doctors. According to the whistleblower, making the sheets easy to fill out and give to patients was intended to induce off-label Xibrom prescriptions. The sales effort reached beyond what a representative said in the room to the instructions a patient took home. That is a concrete connection between a sales budget and the prescribing the company sought.

Public Citizen’s study looked beyond the isolated sales pitch to the campaign a company built:

The Speaker’s Fee Is Part of the Story

A physician speaker’s payment raises a question about what the company was buying. The speaker-program kickback cases examine the purpose of the fee, the selection of the speaker and the prescribing the company sought in return.

In a separate whistleblower complaint against Incyte, the alleged distinction between medical education and purchased prescriptions was blunt:

An employee who knows why a particular prescriber received the invitation holds a part of that account that the presentation slides never show.

Novartis supplied an admitted example in its July 2020 speaker-program settlement. The company admitted conduct that included prescribing inducements, repeated dinners and events that did not occur. An educational event that never happened can still do its job if the job was to pay the prescriber.

That is why the Xyrem sales-and-speaker distinction is useful to a civil whistleblower inquiry. The permission to answer a medical question describes the communication. The invitation, the fee and the prescribing expectations describe the business arrangement around it.

From the Prescription to the Government’s Payment

A pharmaceutical False Claims Act case connects knowing conduct to a false claim for payment by a federal health care program. A manufacturer can cause a pharmacy or physician to submit that claim even when the manufacturer does not submit it itself. That connection is central to the pharmaceutical fraud cases involving promotion and reimbursement.

The use for which the drug was prescribed matters to coverage. Medicaid’s definition of a medically accepted indication includes a use approved by the Food and Drug Administration and certain uses supported by recognized drug references, called compendia. Those medical-reference listings can connect an off-label use to payment. The prescription, the coverage basis and the information used to obtain reimbursement therefore carry parts of the story that a sales presentation leaves out. When a company causes false claims to reach Medicaid, taxpayers pay for the scheme.

For someone in sales, medical affairs or reimbursement support, the valuable knowledge is how the company’s explanation of the drug traveled through those steps.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know How the Answer Reached the Doctor

If you know how a medical question became a sales answer, or why a prescriber became a paid speaker, talk with our whistleblower experts about the campaign behind it. We build the case with you and bring in pharmaceutical fraud whistleblower lawyers who understand promotional science, speaker payments and reimbursement. We stay beside you as we turn that inside knowledge into your strongest pharmaceutical whistleblower case.